Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 1

Status

Completed 9Recruiting 6Active not recruiting 3Withdrawn 1Terminated 1Suspended 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 77Breast Neoplasms 46Colorectal Neoplasms 42Neoplasms 41Neoplasm Metastasis 34Melanoma 31Multiple Myeloma 30Prostatic Neoplasms 29Recurrence 28Stomach Neoplasms 27Pancreatic Neoplasms 27Squamous Cell Carcinoma of Head and Neck 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Lung Neoplasms 26Carcinoma, Renal Cell 25Ovarian Neoplasms 23Lymphoma, Large B-Cell, Diffuse 22Leukemia, Myeloid, Acute 22Triple Negative Breast Neoplasms 21Lymphoma, Non-Hodgkin 21Lymphoma, Follicular 21Leukemia, Lymphocytic, Chronic, B-Cell 19Glioblastoma 19Myelodysplastic Syndromes 17Uterine Cervical Neoplasms 16Lymphoma 16Colonic Neoplasms 15Carcinoma, Transitional Cell 15Lymphoma, Mantle-Cell 14Leukemia 14

Interventions

pembrolizumab 1cemiplimab 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Hereditary Sensory and Autonomic Neuropathies × Clear all
NCT05882734 2026-05-28

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

EMD Serono

Phase 1/2 Active not recruiting
61 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT04520269 2025-09-25

A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)

National University Hospital, Singapore

Phase 1/2 Active not recruiting
74 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05128487 2024-11-25

A Study of NDI 1150-101 in Patients With Solid Tumors

Nimbus Therapeutics

Phase 1/2 Active not recruiting
106 enrolled
GenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡